TITLE

An update of the Cochrane systematic review ofHelicobacter pylorieradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews

AUTHOR(S)
Moayyedi, Paul; Deeks, Jon; Tailey, Nicholas J.; Delaney, Brendan; Forman, David
PUB. DATE
December 2003
SOURCE
American Journal of Gastroenterology;Dec2003, Vol. 98 Issue 12, p2621
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES: A Cochrane systematic review on the efficacy of Helicobacter pylon (H. pylon) eradication therapy in nonulcer dyspepsia concluded that this intervention had a small but statistically significant effect in curing symptoms. A systematic review in the Annals of Internal Medicine suggested that there was no statistically significant effect of H. pylon eradication therapy on nonulcer dyspepsia symptoms. We updated the Cochrane review and explored reasons for these discrepant results. METHODS: In our update of the Cochrane review we included randomized controlled trials evaluating H. pylon eradication in nonulcer dyspepsia published up to September, 2002. A statistician and the lead author of two negative randomized controlled trials explored reasons for the differences between the Cochrane and Annals systematic reviews according to the review methodology, data analyzed, and statistical methods. Sensitivity analyses were undertaken to evaluate which differences had an impact on the review conclusions. RESULTS: The updated review identified 12 trials evaluating H. pylon eradication versus placebo antibiotics in 2903 patients. H. pylon eradication reduced nonulcer dyspepsia (nonulcer dyspepsia relative risk = 0.91; 95% CI = 0.86-0.95). We identified five differences in methodology between the Cochrane and Annals reviews. The Annals review included all dual, triple, and quadruple H. pylon eradication therapies searched until December, 1999; did not contact authors for further information; included abstracts; and assumed that dropouts were treatment failures. The Cochrane review included only those therapies proved to be successful in eradicating H. pylon; searched until May, 2000; contacted authors for further information; included abstracts only if further information was available; and excluded dropouts from the analysis. Not including trials published in 2000 reduced the number of trials in the review and the number of patients evaluated, changing the conclusions from evidence of benefit to benefit not being proved. The method of statistical analysis did not alter conclusions when all studies were included. CONCLUSIONS: The results of systematic reviews in a rapidly developing field depend on inclusion of all relevant studies. There is evidence for a small benefit of eradicating H. pylon in nonulcer dyspepsia, and this is confirmed by updating the Cochrane systematic review.
ACCESSION #
15182471

 

Related Articles

  • COST EFFECTIVENESS OF H PYLORI 'TEST AND TREAT' VERSUS PPI FOR UNINVESTIGATED DYSPEPSIA: MODELLING AND META-ANALYSIS IN THE DESIGN OF THE MRC-CUBE TRIAL. Delaney, B.C.; Moayyedi, P.; Logan, R.F.A.; Qume, M.; Roalfe, A.; Wilson, S.; Barton, P. // Gut;Apr2003 Supplement 1, Vol. 52, pA80 

    Background: Only a small number of trials have directly addressed the management of patients with "uninvestigated" dyspepsia. The design of trials to determine cost effectiveness is more complex than efficacy trials, and can be enhanced by pre-trial modelling. Methods: A simulation model of 72...

  • Triple therapies plus different probiotics for Helicobacter pylori eradication. SCACCIANOCE, G.; ZULLO, A.; HASSAN, C.; GENTILI, F.; CRISTOFARI, F.; CARDINALE, V.; GIGLIOTTI, F.; PIGLIONICA, D.; MORINI, S. // European Review for Medical & Pharmacological Sciences;Jul/Aug2008, Vol. 12 Issue 4, p251 

    The Helicobacter pylori (H. pylori) cure rate following standard triple therapies is decreasing worldwide. Therefore, further approaches aimed to improve standard triple therapy efficacy should be attempted. This prospective, pilot study aimed to evaluate the therapeutic role of either...

  • Sequential Therapy or Triple Therapy for Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Randomized Controlled Trials in Adults and Children. Gatta, Luigi; Vakil, Nimish; Leandro, Gioacchino; Di Mario, Francesco; Vaira, Dino // American Journal of Gastroenterology;Dec2009, Vol. 104 Issue 12, p3069 

    OBJECTIVES:Eradication rates with triple therapy (TT) for Helicobacter pylori infection have declined to unacceptable levels. Sequential therapy (ST) is a novel treatment that has shown promise in several controlled trials. Our aim was to assess the efficacy of ST in adults and children compared...

  • Helicobacter pylori Eradication Therapy: Current Availabilities. Gasparetto, M.; Pescarin, M.; Guariso, G. // ISRN Gastroenterology;2012, p1 

    Background. Though Helicobacter pylori (HP) infections have progressively declined throughout most of the industrialized countries, a gradual increase in failure of HP eradication treatments is observed. Aim. To critically review evidence on the efficacy of the therapeutic availabilities for HP...

  • Long-Term Outcome of Triple Therapy in Helicobacter pylori- Related Nonulcer Dyspepsia: A Prospective Controlled Assessment. Bor-Shyang Sheu; Ching-Yih Lin; Xi-Zhang Lin; Shu-Chu Shiesh; Hsiao-Bai Yang; Chiung-Yu Chen // American Journal of Gastroenterology;Mar1996, Vol. 91 Issue 3, p441 

    Objective: To ascertain whether triple therapy alters the history of Helicobacter pylori (HP)-related nonulcer dyspepsia (NUD). Methods: Forty-one young (<45 yr) dyspeptic patients were confirmed in be HP-related NUD by serology, rapid urease test, and astral biopsy. Endoscopy excluded the...

  • Economic consequences of near-patient test results: the case of tests for the Helicobacter Pylori bacterium in dyspepsia. Fauli, Siri; Thue, Geir // European Journal of Health Economics;Sep2008, Vol. 9 Issue 3, p221 

    We have developed a model for economic evaluation related to the diagnostic accuracy (sensitivity and specificity) of near patient tests used in office laboratories, as opposed to using hospital-based tests. Blood-sample based tests to detect the bacterium Helicobacter Pylori (HP) are useful in...

  • Test-and-Treat Strategy for Dyspepsia Is Supported. Walling, Anne D. // American Family Physician;8/15/2002, Vol. 66 Issue 4, p660 

    Presents an abstracts of studies on dyspepsia. 'Treating Helicobacter pylori in Primary Care Patients With Uninvestigated Dyspepsia: The Canadian Adult Dyspepsia Empiric Treatment--Helicobacter pylori Positive (CADET-Hp) Randomised Controlled Trial,' by N. Chiba et al., from the April 27, 2002...

  • Chronic Gastritis in Dermatitis Herpetiformis: A Controlled Study. Alakoski, Anna; Salmi, Teea T.; Hervonen, Kaisa; Kautiainen, Hannu; Salo, Maarit; Kaukinen, Katri; Reunala, Timo; Collin, Pekka // Clinical & Developmental Immunology;2012, p1 

    Background and Objective. Previous small studies suggest that chronic atrophic gastritis is common in dermatitis herpetiformis (DH). We here examined the frequency and topography of chronic gastritis in 93 untreated DH subjects and in 186 controls with dyspepsia. Methods. Specimens were drawn...

  • NONULCER DYSPEPSIA: HELICOBACTOR PYLORI OR IDIOPATHY? Kozol, Robert A. // American Journal of Gastroenterology;Mar1996, Vol. 91 Issue 3, p419 

    Discusses an overview of studies on anti-Helicobacter pylori therapy in patients with functional or non ulcer dyspepsia. Advantage of the eradication of Helicobacter pylori in patients with peptic ulcer; Result of clinical trials of anti-Helicobacter pylori therapy; Strengths of the study...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics